These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 35721659)

  • 1. Rapid-Onset Opioids for Management of Breakthrough Cancer Pain: Considerations for Daily Practice.
    Bossi P; Escobar Y; Pea F
    Front Pain Res (Lausanne); 2022; 3():893530. PubMed ID: 35721659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
    Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A
    Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breakthrough cancer pain (BTcP): a synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy.
    Zucco F; Bonezzi C; Fornasari D
    Adv Ther; 2014 Jul; 31(7):657-82. PubMed ID: 25005168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing.
    Mercadante S
    Crit Rev Oncol Hematol; 2011 Dec; 80(3):460-5. PubMed ID: 21215653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breakthrough cancer pain treatment in Spain: physicians' perception of current opioids utilization and prescription.
    Villegas Estévez F; López Alarcón MD; Alonso Babarro A; Olay Gayoso L; de Castro J; Lería-Gelabert M; Melogno-Klinkas M
    Curr Med Res Opin; 2020 Aug; 36(8):1383-1391. PubMed ID: 32453602
    [No Abstract]   [Full Text] [Related]  

  • 6. Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPS-MS study.
    Mercadante S; Adile C; Masedu F; Marchetti P; Costanzi A; Aielli F
    Eur J Pain; 2019 Apr; 23(4):719-726. PubMed ID: 30421474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bibliometric Network Analysis on Rapid-Onset Opioids for Breakthrough Cancer Pain Treatment.
    Cascella M; Monaco F; Nocerino D; Chinè E; Carpenedo R; Picerno P; Migliaccio L; Armignacco A; Franceschini G; Coluccia S; Gennaro PD; Tracey MC; Forte CA; Tafuri M; Crispo A; Cutugno F; Vittori A; Natoli S; Cuomo A
    J Pain Symptom Manage; 2022 Jun; 63(6):1041-1050. PubMed ID: 35151801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
    Mercadante S; Ferrera P; Adile C; Casuccio A
    J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioids for the management of breakthrough pain in cancer patients.
    Zeppetella G; Davies AN
    Cochrane Database Syst Rev; 2013 Oct; (10):CD004311. PubMed ID: 24142465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment and treatment of breakthrough cancer pain: from theory to clinical practice.
    Vellucci R; Mediati RD; Gasperoni S; Mammucari M; Marinangeli F; Romualdi P
    J Pain Res; 2017; 10():2147-2155. PubMed ID: 29066928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose fentanyl sublingual spray for breakthrough cancer pain.
    Taylor DR
    Clin Pharmacol; 2013; 5():131-41. PubMed ID: 23901300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once again... breakthrough cancer pain: an updated overview.
    Mercadante S
    J Anesth Analg Crit Care; 2023 Jul; 3(1):23. PubMed ID: 37480136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fentanyl for the treatment of tumor-related breakthrough pain.
    Bornemann-Cimenti H; Wejbora M; Szilagyi IS; Sandner-Kiesling A
    Dtsch Arztebl Int; 2013 Apr; 110(16):271-7. PubMed ID: 23671467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating breakthrough pain in oncology.
    Mercadante S
    Expert Rev Anticancer Ther; 2018 May; 18(5):445-449. PubMed ID: 29478355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer.
    Magnani C; Giannarelli D; Calvieri A; Dardeli A; Eusepi G; Restuccia MR; Mastroianni C; Casale G
    Postgrad Med J; 2018 Oct; 94(1116):566-570. PubMed ID: 30317182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fentanyl for breakthrough cancer pain: where are we?
    Meriggi F; Zaniboni A
    Rev Recent Clin Trials; 2013 Mar; 8(1):42-7. PubMed ID: 23259417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of intranasal fentanyl in breakthrough pain management in cancer patients.
    Leppert W
    Cancer Manag Res; 2010 Sep; 2():225-32. PubMed ID: 21188114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breakthrough pain in patients with head & neck cancer. A secondary analysis of IOPS MS study.
    Mercadante S; Masedu F; Valenti M; Aielli F
    Oral Oncol; 2019 Aug; 95():87-90. PubMed ID: 31345399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canadian recommendations for the management of breakthrough cancer pain.
    Daeninck P; Gagnon B; Gallagher R; Henderson JD; Shir Y; Zimmermann C; Lapointe B
    Curr Oncol; 2016 Apr; 23(2):96-108. PubMed ID: 27122974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care.
    Chang A; Roeland EJ; Atayee RS; Revta C; Ma JD
    J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):247-60. PubMed ID: 26368648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.